Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone303-703-4906
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$23.43 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/29/2019 (Estimated)
OptionableNot Optionable
Zynex (OTCMKTS:ZYXI) Frequently Asked Questions
What is Zynex's stock symbol?
Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."
How were Zynex's earnings last quarter?
Zynex Inc. (OTCMKTS:ZYXI) announced its quarterly earnings data on Wednesday, July, 31st. The company reported $0.06 earnings per share for the quarter, meeting analysts' consensus estimates of $0.06. The company earned $10.30 million during the quarter, compared to analyst estimates of $9.84 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%. View Zynex's Earnings History.
When is Zynex's next earnings date?
What guidance has Zynex issued on next quarter's earnings?
Zynex issued an update on its third quarter 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10.7-11.2 million, compared to the consensus revenue estimate of $10.3 million.
What price target have analysts set for ZYXI?
2 equities research analysts have issued 1 year target prices for Zynex's shares. Their forecasts range from $10.75 to $12.00. On average, they expect Zynex's stock price to reach $11.38 in the next year. This suggests a possible upside of 8.5% from the stock's current price. View Analyst Price Targets for Zynex.
What is the consensus analysts' recommendation for Zynex?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynex.
Has Zynex been receiving favorable news coverage?
Media headlines about ZYXI stock have trended somewhat positive on Sunday, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zynex earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Zynex.
Who are some of Zynex's key competitors?
Some companies that are related to Zynex include Natus Medical (NTUS), Natus Medical (BABY), InMode (INMD), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), BioLife Solutions (BLFS), Semler Scientific (SMLR), Viewray (VRAY), Stereotaxis (STXS), BioSig Technologies (BSGM), Rockwell Medical (RMTI), Edap Tms (EDAP), Fonar (FONR) and Second Sight Medical Products (EYES).
What other stocks do shareholders of Zynex own?
Who are Zynex's key executives?
Zynex's management team includes the folowing people:
- Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)
- Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)
- Mr. David B. Mogill, VP of Operations
- Mr. Robert Bird, VP of Marketing
- Mr. Steve Siefring, Director of Bus. Devel.
How do I buy shares of Zynex?
Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zynex's stock price today?
One share of ZYXI stock can currently be purchased for approximately $10.48.
How big of a company is Zynex?
Zynex has a market capitalization of $340.16 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. View Additional Information About Zynex.
What is Zynex's official website?
How can I contact Zynex?
Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]
MarketBeat Community Rating for Zynex (OTCMKTS ZYXI)
MarketBeat's community ratings are surveys of what our community members think about Zynex and other stocks. Vote "Outperform" if you believe ZYXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
